Trial Profile
A Phase I/II Study of the ALK Inhibitor CH5424802/RO5424802 in Patients With ALK-Rearranged Non-Small Cell Lung Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 21 Sep 2017
Price :
$35
*
At a glance
- Drugs Alectinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Roche
- 21 Feb 2017 Results published in a Roche media release.
- 21 Feb 2017 According to a Roche media release, the European Commission has granted a conditional marketing authorisation for Alecensa (alectinib) as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib. The approval was based on data from this and another trial (NP28673).
- 16 Dec 2016 According to a Roche media release, the Committee for Medicinal Products for Human Use (CHMP) of EMA has adopted a positive opinion for the use of Alecensa (alectinib) for the treatment of adult patients with advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) whose disease has progressed following treatment with crizotinib. The opinion was based on data from this and another trial (NP28673).